Concord Biotech Ltd Reports FY 2024-2025 Financial Results with 78% Turnover from API Manufacturing

Concord Biotech Ltd, a research-driven biopharmaceutical company, has reported its financial results for FY 2024-2025. The company's business activities primarily revolve around the manufacturing of pharmaceuticals, with 78% of the turnover coming from the manufacturing of active pharmaceutical ingredients (APIs) and 22% from finished formulations. The company's products are sold in over 70 countries, with 45% of the total turnover coming from exports. Concord Biotech serves both national and international markets, including the United States, Latin America, the Middle East, and Southeast Asia. The company operates through B2B and B2C channels, partnering with government and corporate hospitals to deliver healthcare solutions directly to end patients. The company supports global biopharmaceutical companies in fermentation, semi-synthetic APIs, and finished formulations, undertaking advanced activities such as strain improvement, media and process optimization, and scale-up from R&D to pilot and commercial production. The company has a robust portfolio catering to over 250 customers across more than 70 countries.